N-{3-{4-{[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl}acrylamide

ID: ALA4787483

Chembl Id: CHEMBL4787483

PubChem CID: 162667731

Max Phase: Preclinical

Molecular Formula: C27H21ClN6O2

Molecular Weight: 496.96

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C=CC(=O)Nc1cccc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)c1

Standard InChI:  InChI=1S/C27H21ClN6O2/c1-2-24(35)33-18-8-5-6-17(12-18)21-14-30-26-25(21)27(32-16-31-26)34-19-9-10-23(22(28)13-19)36-15-20-7-3-4-11-29-20/h2-14,16H,1,15H2,(H,33,35)(H2,30,31,32,34)

Standard InChI Key:  GOAJIFLFYKGQGD-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4787483

    ---

Associated Targets(Human)

EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AKT2 Tchem Serine/threonine-protein kinase AKT (245 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 496.96Molecular Weight (Monoisotopic): 496.1415AlogP: 6.12#Rotatable Bonds: 8
Polar Surface Area: 104.82Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.18CX Basic pKa: 5.54CX LogP: 5.23CX LogD: 5.22
Aromatic Rings: 5Heavy Atoms: 36QED Weighted: 0.22Np Likeness Score: -1.38

References

1. Lategahn J,Hardick J,Grabe T,Niggenaber J,Jeyakumar K,Keul M,Tumbrink HL,Becker C,Hodson L,Kirschner T,Klövekorn P,Ketzer J,Baumann M,Terheyden S,Unger A,Weisner J,Müller MP,van Otterlo WAL,Bauer S,Rauh D.  (2020)  Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.,  63  (20.0): [PMID:32931277] [10.1021/acs.jmedchem.0c00870]

Source